# Gracell Biotechnologies (stock symbol: GRCL) Logo in transparent PNG and SVG formats

## Gracell Biotechnologies Logo large

### Gracell Biotechnologies Logo large Download PNG (40.82 KB)

![Gracell Biotechnologies Logo large Download PNG (40.82 KB)](/img/orig/GRCL_BIG-b6e58c9b.png)

### Gracell Biotechnologies Logo large Download SVG (2.55 KB)

![Gracell Biotechnologies Logo large Download SVG (2.55 KB)](/img/orig/GRCL_BIG-c109475c.svg)

## Gracell Biotechnologies Logo icon format

### Gracell Biotechnologies Logo icon format Download PNG (63.14 KB)

![Gracell Biotechnologies Logo icon format Download PNG (63.14 KB)](/img/orig/GRCL-375dce5d.png)

### Gracell Biotechnologies Logo icon format Download SVG (1.11 KB)

![Gracell Biotechnologies Logo icon format Download SVG (1.11 KB)](/img/orig/GRCL-8bfad001.svg)

## Gracell Biotechnologies Logo large for dark backgrounds

### Gracell Biotechnologies Logo large for dark backgrounds Download PNG (39.71 KB)

![Gracell Biotechnologies Logo large for dark backgrounds Download PNG (39.71 KB)](/img/orig/GRCL_BIG.D-ffcc5286.png)

### Gracell Biotechnologies Logo large for dark backgrounds Download SVG (2.55 KB)

![Gracell Biotechnologies Logo large for dark backgrounds Download SVG (2.55 KB)](/img/orig/GRCL_BIG.D-1668a387.svg)

## Gracell Biotechnologies Logo icon format for dark backgrounds

### Gracell Biotechnologies Logo icon format for dark backgrounds Download PNG (60.73 KB)

![Gracell Biotechnologies Logo icon format for dark backgrounds Download PNG (60.73 KB)](/img/orig/GRCL.D-94e74311.png)

### Gracell Biotechnologies Logo icon format for dark backgrounds Download SVG (1.11 KB)

![Gracell Biotechnologies Logo icon format for dark backgrounds Download SVG (1.11 KB)](/img/orig/GRCL.D-201bce50.svg)

## About Gracell Biotechnologies

Gracell Biotechnologies Inc., a clinical-stage biopharmaceutical company, primarily discovers and develops cell therapies for the treatment of cancer in the People's Republic of China. Its lead product candidates include GC012F, a FasTCAR-enabled dual BCMA- and CD19-directed autologous CAR-T product candidate that is in Phase I trial for the treatment of multiple myeloma; GC019F, a FasTCAR-enabled CD19-directed autologous CAR-T product candidate, which is in Phase I clinical trial for the treatment of adult B cell acute lymphoblastic leukemia (B-ALL), as well as in preclinical stage for the treatment of relapsed or refractory (r/r) B cell non-Hodgkin's lymphoma (B-NHL); and GC027, a TruUCAR-enabled CD7-directed allogeneic CAR-T product candidate, which is in Phase I clinical trial for the treatment of adult T cell acute lymphoblastic leukemia. The company's product candidates also comprise GC007g, a donor-derived CD19-directed allogeneic CAR-T cell therapy that is in Phase 1/2 registrational trial clinical trial for the treatment of r/r B-ALL; and GC502, a TruUCAR-enabled dual CD19- and CD7 -directed, off-the-shelf allogeneic CAR-T product candidate, which is in Phase I trial for the treatment of B-cell malignancies. In addition, it has a portfolio of earlier stage product candidates targeting various cancer indications, such as ovarian cancer, breast cancer, peripheral T cell lymphoma, a subtype of NHL, and T cell lymphoblastic leukemia. The company was founded in 2017 and is headquartered in Suzhou, China.

1. Website domain: gracellbio.com
2. Employees: 348
3. Marketcap: $0.11 Billion USD


## Categories
- [x] ðŸ‡¨ðŸ‡³ China
- [x] ðŸ’Š Pharmaceuticals
- [x] ðŸ§¬ Biotech
